Bavarian Nordic A/S Bavarian Nordic A/S

Bavarian Nordic A/S

BAVA

Ранг среди акций #4997
Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in... Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in the research, production, and global distribution of vital, life-saving vaccines. The company's commercialized offerings include non-replicating vaccines for smallpox and monkeypox, marketed as IMVAMUNE, IMVANEX, and JYNNEOS. Additionally, their portfolio features Rabipur/RabAvert for rabies prevention, Encepur for tick-borne encephalitis, and MVABEA, an Ebola vaccine. Bavarian Nordic also maintains a robust pipeline of investigational treatments. This includes MVA-BN (freeze-dried), which has successfully completed Phase III clinical trials for smallpox; MVA-BN RSV, currently in Phase III development for respiratory syncytial virus; ABNCoV2, which completed Phase II trials targeting SARS-CoV-2; and TAEK-VAC, presently in Phase I/II trials for advanced HER2 and brachyury-expressing cancers. The firm engages in key partnerships, notably a license and collaboration agreement with AdaptVac, and licensing agreements with both the National Cancer Institute and the Public Health Service. Bavarian Nordic operates across a wide international footprint, with a presence in countries such as the United States, Germany, Belgium, France, Canada, the United Kingdom, Hong Kong, Saudi Arabia, Australia, Switzerland, and numerous other global markets.
Цена акции
$38.42
Последняя синхронизация: 2026-10-20
Рыночная капитализация
$2.92B
Изменение (1 день)
1.77%
Изменение (1 год)
3.23%
Страна
DK
Торговля Bavarian Nordic A/S (BAVA)

Категория

Healthcare
Прибыль Bavarian Nordic A/S (BAVA)
Прибыль на 2026 TTM: 0
Согласно последним финансовым отчетам Bavarian Nordic A/S, текущая прибыль компании составляет 0. В 2026 году компания получила прибыль 0, равна прибыли за 2026, которая составила 0. Отображаемая прибыль на этой странице — это прибыль до уплаты процентов и налогов, или просто EBIT.
История прибыли компании Bavarian Nordic A/S с 2026 по 2026
Прибыль в конце каждого года
Год Прибыль Изменить
Недостаточно данных для указанных дат.
Прибыль схожих компаний или конкурентов
Компания Прибыль Разница в прибыли Страна
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL